<cite id="uufuy"><noscript id="uufuy"></noscript></cite>
    <rp id="uufuy"></rp>

    INVENTING A NEW
    ROADMAP FOR BIOTECH

    Every day, we use our homegrown technologies to discover, develop, research and deliver new medicines that help people with serious diseases. Watch to see what drives us.

    Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases.

    Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite? technologies, such as VelocImmune? which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

    FOR 30 YEARS, OUR
    MISSION HAS BEEN TO
    USE THE POWER OF
    SCIENCE TO BRING
    NEW MEDICINES TO
    PATIENTS... OVER
    AND OVER AGAIN.

    Neil Stahl, PhD, Executive VP,
    Research and Development

    2018 annual report PDF download

    Check out our 2018 annual materials. The Responsibility Report and Annual Report are now online.

    Read our annual report
    and responsibility report

    2018 responsibility report PDF download

    REGENERON BY THE NUMBERS

    • 30
      years of scientific
      leadership
    • 7,300+
      employees
      worldwide
    • 700+
      employees with
      an MD, PhD or
      PharmD degree
    • 6TH
      consecutive year
      in Forbes' World's
      Most Innovative
      Companies
    • #1
      ranking in Science
      magazine’s global Top
      Employer survey for six
      of the past eight years
    • 31,000+
      employee volunteer hours
      for 100+ organizations
      in 2018
    • 7
      FDA-approved
      medicines
    • 94%
      of our waste
      diverted from
      landfill, reaching
      our goal
    • 100%
      of drug candidates
      invented and
      developed in-house
    • 500,000+
      exomes sequenced
      to date
    • 100+
      publications in 2018
    • 20
      product candidates in
      clinical development
      across multiple
      therapeutic areas
    • Shingo Institute: The Shingo Prize, 2019

      Great Places to Work: Best Workplace in Ireland, 2019

      Science: #1 Top Employer, 2018

      Forbes: Top 10 Most Innovative Companies, 2018

      Civic 50: Most Community-Minded Companies in the Nation, 2018

      Fortune: Best Companies to Work for, 2018

    • MIT Technology Review: Top 10 Smartest Companies, 2017

      Fortune: Future 50, 2017

      Barron’s: World’s Best CEOs, 2016

      Scrip Award: R&D Team of the Year, 2016

      Crain’s New York Business: Fast 50, 2015

    LEADERSHIP

    We are the only biopharmaceutical company to be led by physician-scientists for more than 30 years. We consistently demonstrate our commitment to scientific excellence by counting multiple Nobel Laureates and five members of the National Academy of Sciences among our leadership, as well as being one of the first companies to form a Science and Technology Committee as an integral component of its Board, a practice which has since become industry standard.

    Our leadership

    A FOCUS
    ON SCIENCE

    From our first days, science has remained our central guiding principle.

    Our journey

    免费四虎库精品视倾